prokinetiikkaan

Prokinetix is a neuroscientific company based in the United States that focuses on the development of therapeutics for gastrointestinal (GI) motility disorders. The company's name, prokinetix, is derived from the term "prokinetic," which refers to medications that enhance gut motility.

Prokinetix was founded in 2018 with the goal of addressing the significant unmet medical need for treatments of GI motility disorders. The company's research is focused on identifying novel targets and developing new therapies for conditions such as gastroparesis, constipation, and chronic constipation-predominant irritable bowel syndrome (IBS-C).

Prokinetix's research is centered on the discovery of small molecule drugs that can modulate the gut microbiome and enhance gut motility. The company's early-stage research has made significant discoveries in this area, including the identification of novel molecular targets for gut motility and the development of preclinical models for GI motility disorders.

Prokinetix's research has potential implications for the treatment of a range of GI motility disorders. Given the high prevalence of these conditions and the lack of effective treatments, the company's research has significant potential to improve the lives of millions of people. The company's work has been recognized by various industry organizations and research institutions, and its research continues to advance the understanding of GI motility and the development of new treatments for these disorders.